Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy | Zendy

Mohamed ElKhalawany | Zendy; Shabaan | Zendy; Sultan Sultan | Zendy; FatmaM.A Al-Salam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy

Author(s) -

Mohamed ElKhalawany,

Shabaan,

Sultan Sultan,

FatmaM.A Al-Salam

Publication year - 2011

Publication title -

clinical cosmetic and investigational dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.73

H-Index - 35

ISSN - 1178-7015

DOI - 10.2147/ccid.s26200

Subject(s) - medicine , angiogenesis , immunostaining , cd31 , cd34 , neovascularization , leprosy , minocycline , group b , high power field , group a , lepromatous leprosy , cd68 , immunohistochemistry , pathology , gastroenterology , antibiotics , stem cell , biology , microbiology and biotechnology , genetics

Angiogenesis was suggested to have a significant role in the pathogenesis of leprosy. However, the benefit of inhibiting angiogenesis in lepromatous leprosy patients has not previously been studied. The purpose of this study was to evaluate angiogenesis in leprosy patients before and after treatment with multidrug therapy (MDT) with and without minocycline.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research